Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Refocus, Optimize, Externalize: Takeda Overhauls Global R&D

Executive Summary

As it reported solid underlying growth in the fiscal first quarter, Takeda has unveiled a detailed implementation program for its stated strategic intent to refocus global R&D effort on selected R&D areas, in a major overhaul that will make much wider use of external partners and affect "significant" numbers of people across the company.


Related Content

Takeda Extends PRA Alliance To Japan With New JV
Takeda Acquires Ariad In $5.2bn Deal – US Infrastructure A Key Component?
New Bridge Venture Aligns With Takeda Externalization Strategy
Will Japan Pharma Fall In Line With R&D Externalization Trends?
Japan Issues Strong Warning Over Brexit
Takeda Chooses PRA To Lead Its Revamped Clinical Development Ops
Takeda Deepens Links As London Touts Life Science Credentials


Related Companies